On World Lymphoma Awareness Day, a Spotlight on the Blood-Cancer Innovators in the PRISM Indexes

September 15 — World Lymphoma Awareness Day

Every year on September 15, patient groups, clinicians, and researchers mark World Lymphoma Awareness Day to raise recognition of a cancer that too often hides in plain sight. Lymphoma is a cancer of the lymphatic system — the network of vessels, nodes, and organs that helps the body fight infection. It arises when lymphocytes, a type of white blood cell, grow uncontrollably. Broadly, the disease splits into two families: Hodgkin lymphoma, defined by the presence of Reed-Sternberg cells, and the far larger and more varied group of non-Hodgkin lymphomas (NHL), which includes aggressive forms such as diffuse large B-cell lymphoma (DLBCL) as well as slower-growing subtypes and T-cell malignancies.

Because early symptoms — swollen lymph nodes, fatigue, night sweats, unexplained weight loss — can mimic far more common ailments, awareness matters. Earlier recognition can mean earlier diagnosis, and for many lymphoma subtypes, the treatment landscape has been transformed over the past decade.

Why this day matters to markets, too

Few areas of oncology have advanced as dramatically as blood cancer. The arrival of CAR-T cell therapy, bispecific antibodies, antibody-drug conjugates (ADCs), and next-generation immunotherapies has rewritten outcomes for patients who once had few options. That scientific momentum is mirrored across the small- and micro-cap names that make up the PRISM MarketView Biotech and Pharmaceuticals indexes, where a meaningful cluster of companies is working on the mechanisms most relevant to lymphoma and related blood cancers.

Below is a cross-referenced look at PRISM index constituents whose science touches lymphoma, blood-cancer pipelines, cell therapy, and immunotherapy.

Cell therapy: the “living drug” frontier

Allogene Therapeutics (ALLO) — PRISM Biotech Index. Allogene is a leading name in allogeneic, or “off-the-shelf,” CAR-T therapy — an approach that aims to deliver engineered cell therapy from healthy-donor cells rather than a patient’s own, potentially widening access. Its lead work has centered on large B-cell lymphoma, one of the most closely watched arenas in cell therapy.

Immatics (IMTX) — PRISM Biotech Index. Immatics develops T-cell receptor (TCR)-based therapies and T-cell engagers designed to direct the immune system against cancer targets, spanning both solid and hematologic malignancies — a platform squarely in the immuno-oncology conversation that defines modern blood-cancer research.

Immunotherapy and targeted antibodies

TG Therapeutics (TGTX) — PRISM Biotech Index. With one of the larger market caps among the index’s oncology-adjacent names, TG Therapeutics built its reputation around anti-CD20 B-cell biology — the same target class that underpins much of modern B-cell lymphoma treatment.

Corvus Pharmaceuticals (CRVS) — PRISM Pharmaceuticals Index. Corvus has advanced an ITK inhibitor being studied in T-cell lymphoma, part of a broader immunotherapy-driven approach — an important reminder that T-cell lymphomas, historically harder to treat, remain a key area of unmet need.

Innate Pharma (IPHA) — PRISM Biotech Index. Innate specializes in natural killer (NK) cell-based immunotherapy and antibody engineering, with programs that have included cutaneous T-cell lymphoma among their targets.

ALX Oncology (ALXO) — PRISM Biotech Index. ALX Oncology’s work on the CD47 “don’t eat me” checkpoint pathway represents a distinct immunotherapy angle, studied in combination regimens including hematologic settings.

CytomX Therapeutics (CTMX) — PRISM Biotech Index. CytomX is known for conditionally activated antibodies and T-cell engagers designed to concentrate their effect within the tumor — a strategy aimed at widening the therapeutic window in immuno-oncology.

Antibody-drug conjugates and targeted approaches

Pyxis Oncology (PYXS) — PRISM Biotech Index. Pyxis develops antibody-drug conjugates, a modality that has become central to blood-cancer treatment by pairing tumor-targeting antibodies with potent payloads.

Shattuck Labs (STTK) — PRISM Biotech Index. Shattuck’s fusion-protein platform targets immune pathways in hematologic malignancies, extending the immunotherapy toolkit for blood cancers.

Hematology-oncology franchises

Rigel Pharmaceuticals (RIGL) — PRISM Pharmaceuticals Index. One of the index’s stronger performers since inception, Rigel has built a commercial hematology-oncology footprint, reflecting the broader shift toward specialized blood-cancer care.

Actinium Pharmaceuticals (ATNM) — PRISM Pharmaceuticals Index. Actinium focuses on targeted radiotherapy designed to home in on blood-cancer cells and to improve outcomes around transplant and cell-therapy conditioning — a supportive but critical piece of the blood-cancer treatment puzzle.

The bigger picture

What stands out on World Lymphoma Awareness Day is how many of the mechanisms now reshaping lymphoma care — engineered cell therapy, NK-cell and TCR platforms, checkpoint biology, and ADCs — are represented among emerging companies in the PRISM MarketView Biotech and Pharmaceuticals indexes. For patients, that breadth translates into more shots on goal. For investors watching the small- and micro-cap oncology space, it underscores why blood cancer remains one of the most closely followed corners of biotech.

Awareness days do more than educate the public; they remind us of the unmet need still driving this research. Behind every ticker on this list is a program aimed at a patient who might one day hear the words “in remission.”